Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Danaher Beats Out Cytyc, Ventana In Battle For Vision Systems

This article was originally published in The Gray Sheet

Executive Summary

Cytyc and Ventana are bowing out of a bidding war for cancer and infectious disease detection equipment maker Vision Systems, which says it prefers a richer offer valued at $520 mil. from diversified industrial firm Danaher

You may also be interested in...



Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities

Danaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.

Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities

Danaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.

Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid

Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says

Related Content

UsernamePublicRestriction

Register

MT024080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel